Home Support ISMP Newsletters Webinars Report Errors Educational Store Consulting FAQ Tools About Us Contact Us
ISMP Facebook

ISMP Survey about hydromorphone

FDA is working with ISMP to reduce the risk of drug-name mix-ups between morphine and hydromorphone. One of the options under consideration is recommending to manufacturers a consistent way to present the drug name using tall man letters. Please take this short survey to help us reduce the risk of errors with these high-alert medications, as mix-ups have proven deadly at times.

1. Which of the following uses of tall man letters do you believe would best bring attention to the differences between the drug names morphine and hydromorphone?



A different combination of small and tall man letters: (specify)

Tall man letters will not make a difference in preventing mix-ups between morphine and hydromorphone


2. Please list any other error-reduction strategies you use to reduce the risk of drug name mix-ups between morphine and hydromorphone: (specify)

Home | Contact UsEmployment  | Legal Notices | Privacy Policy | Help Support ISMP
Med-ERRS Med-ERRS | MSOMedication Safety Officers Society | Consumer Medication SafetyFor consumers
 ISMP Canada ISMP Canada | ISMP Spain ISMP Spain | ISMP Brasil ISMP Brasil | International Group | Pennsylvania Patient Safety Authority

200 Lakeside Drive, Suite 200, Horsham, PA 19044, Phone: (215) 947-7797,  Fax: (215) 914-1492
© 2018 Institute for Safe Medication Practices. All rights reserved